Physician profile
Jared Wade Barton
NPI 1912561549
$3,817.79
in general payments reported to CMS, 2019-2025
22 companies · $1,143 in 2025
The $1,143 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $135 · 2022: $619 · 2023: $753 · 2024: $1,167 · 2025: $1,143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,063.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,063.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $908.91 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $793.75 | 2022-2025 | Libtayo, Dupixent |
| Lilly USA, LLC | $663.09 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Novartis Pharmaceuticals Corporation | $248.48 | 2023-2024 | |
| Sun Pharmaceutical Industries INC. | $233.09 | 2021-2025 | |
| Janssen Biotech, INC. | $164.13 | 2022-2025 | Tremfya, Simponi Aria, Stelara |
| Mimedx Group, INC. | $162.86 | 2024-2025 | |
| Ucb, INC. | $158.33 | 2022-2025 | Bimzelx |
| Genzyme Corporation | $98.76 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $88.45 | 2024 | Sotyktu |
| Zimmer Biomet Holdings, INC. | $47.22 | 2023 | Zeos |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $42.61 | 2023-2025 | Jublia, Cabtreo |
| Kerecis Limited | $40.92 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Organon LLC | $28.45 | 2025 | Vtama |
| Incyte Corporation | $25.81 | 2025 | Opzelura |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $23.50 | 2025 | Via Matrix |
| Paratek Pharmaceuticals, INC. | $18.03 | 2025 | Nuzyra |
| Galderma Laboratories, L.P. | $16.49 | 2025 | Nemluvio |
| Medtronic, INC. | $14.53 | 2025 | Venaseal |
| Arcutis Biotherapeutics, INC. | $14.51 | 2023 | |
| Verrica Pharmaceuticals INC. | $14.14 | 2023 | Ycanth |
| Kowa Pharmaceuticals America, INC. | $11.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Barton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.